Characterization of vasoactive intestinal peptide receptors in canine liver membranes.

Kiso T, Ito S, Ohta T, Asano T, Nakazato Y

Biochemical pharmacology1 Jan 1994Cited by 2 (Europe PMC)

PMID8304967DOI10.1016/0006-2952(94)90012-4PepBankPUB-08304967

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

01LabEx vivo tissueActivity measurement
In canine liver membranes, 125I-VIP bound in a reversible, saturable, specific and temperature-dependent manner.
In plain wordsIn lab tests with dog liver membranes, VIP bound to the membranes in a specific, saturable and reversible way.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableVIP binding to canine liver membranes
Study
dogn: not reported in source
canine liver membranes (rat liver membranes for comparison)
Outcome group
Receptor activity and mechanism · Pharmacology
Studied dose
Dose not stated
Source sentences
Summary
The binding of VIP to canine liver membranes occurred in a reversible, saturable, specific and temperature-dependent manner.
1 context sentence(design, population, supporting numbers)
Summary · context
The binding characteristics of vasoactive intestinal peptide (VIP) in the liver membranes of the dog were examined using radioligand binding assay with 125I-VIP and unlabelled peptides and results were compared with those from the rat.
Report a problemFND-0830496701
02LabEx vivo tissueActivity measurement
In canine liver membranes, guanine nucleotides inhibited VIP binding in a dose-dependent manner.
In plain wordsIn lab tests with dog liver membranes, guanine nucleotides reduced VIP binding as the dose rose.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseEffect of guanine nucleotides on VIP binding
Study
dogn: not reported in source
canine liver membranes (rat liver membranes for comparison)
Outcome group
Receptor activity and mechanism · Pharmacology
Studied dose
Dose not stated
Source sentences
Summary
Guanine nucleotides dose-dependently inhibited VIP binding.
1 context sentence(design, population, supporting numbers)
Summary · context
The binding characteristics of vasoactive intestinal peptide (VIP) in the liver membranes of the dog were examined using radioligand binding assay with 125I-VIP and unlabelled peptides and results were compared with those from the rat.
Report a problemFND-0830496702
03LabEx vivo tissueActivity measurement
In canine liver membranes, VIP was the most potent competitor of 125I-VIP binding, followed by PACAP-27, PACAP-38, PHI and secretin; the order differed in rat membranes.
In plain wordsIn lab tests, VIP competed best for its own binding sites in dog liver membranes, and the order of other peptides differed in rat membranes.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableOrder of potency of peptides competing for VIP binding
Study
dogn: not reported in source
canine liver membranes (rat liver membranes for comparison)
Outcome group
Receptor activity and mechanism · Pharmacology
Studied dose
Dose not stated
Source sentences
Summary
The order of potency in competition experiments with unlabelled peptide was: VIP > pituitary adenylate cyclase activating peptide (PACAP)-27 > PACAP-38 >> peptide histidine isoleucine (PHI) = secretin in the dog, and PACAP-27 > PACAP-38 > VIP > PHI > secretin in the rat.
1 context sentence(design, population, supporting numbers)
Summary · context
The binding characteristics of vasoactive intestinal peptide (VIP) in the liver membranes of the dog were examined using radioligand binding assay with 125I-VIP and unlabelled peptides and results were compared with those from the rat.
Report a problemFND-0830496703
04LabEx vivo tissueActivity measurement
In canine liver membranes, PHI and secretin were about 5000 times less potent than VIP, while in rat membranes secretin was about 100 times less potent.
In plain wordsIn lab tests, PHI and secretin were much weaker than VIP at binding to dog liver membranes.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableRelative potency of PHI and secretin versus VIP
Study
dogn: not reported in source
canine liver membranes (rat liver membranes for comparison)
Comparator
VIP
Outcome group
Receptor activity and mechanism · Pharmacology
Studied dose
Dose not stated
Measurements
relative potency of PHI and secretin versus VIP
≈ 5000 fold less potent
dog
relative potency of secretin versus VIP
≈ 100 fold less potent
rat
Source sentences
Summary
PHI and secretin were about 5000 times less potent than VIP in the dog, but secretin was about 100 times less potent than VIP in the rat.
1 context sentence(design, population, supporting numbers)
Summary · context
The binding characteristics of vasoactive intestinal peptide (VIP) in the liver membranes of the dog were examined using radioligand binding assay with 125I-VIP and unlabelled peptides and results were compared with those from the rat.
Report a problemFND-0830496704
05LabEx vivo tissueMechanism
Canine liver membranes have VIP recognition sites that differ from those in rat liver membranes.
In plain wordsIn lab tests, VIP binding sites in dog liver membranes differ from those in rat liver membranes.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableRecognition sites for VIP in canine versus rat liver
Study
dogn: not reported in source
canine liver membranes (rat liver membranes for comparison)
Outcome group
Receptor activity and mechanism · Pharmacology
Studied dose
Dose not stated
Source sentences
Summary
The VIP binding sites in canine liver membranes have recognition sites for VIP which differ from those in rat liver membranes.
1 context sentence(design, population, supporting numbers)
Summary · context
The binding characteristics of vasoactive intestinal peptide (VIP) in the liver membranes of the dog were examined using radioligand binding assay with 125I-VIP and unlabelled peptides and results were compared with those from the rat.
Report a problemFND-0830496705

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.